SteelPeak Wealth LLC Has $2.29 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

SteelPeak Wealth LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 28.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,615 shares of the biopharmaceutical company's stock after buying an additional 792 shares during the quarter. SteelPeak Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $2,293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on REGN. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. The Goldman Sachs Group dropped their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Finally, Citigroup dropped their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $823.54.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded up $7.98 during trading hours on Friday, reaching $567.74. The company had a trading volume of 844,505 shares, compared to its average volume of 917,464. The stock has a 50-day moving average of $545.22 and a two-hundred day moving average of $619.85. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The firm has a market capitalization of $61.29 billion, a PE ratio of 14.45, a PEG ratio of 2.11 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the business posted $9.55 earnings per share. The business's quarterly revenue was down 3.7% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.